594,919 Shares in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) Acquired by Brooklyn FI LLC

Brooklyn FI LLC acquired a new stake in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 594,919 shares of the company's stock, valued at approximately $677,000. Brooklyn FI LLC owned 0.85% of SELLAS Life Sciences Group as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in SLS. XTX Topco Ltd acquired a new stake in SELLAS Life Sciences Group in the third quarter valued at $78,000. Virtu Financial LLC boosted its position in SELLAS Life Sciences Group by 24.1% during the third quarter. Virtu Financial LLC now owns 79,241 shares of the company's stock worth $99,000 after purchasing an additional 15,398 shares in the last quarter. State Street Corp grew its holdings in SELLAS Life Sciences Group by 30.2% in the third quarter. State Street Corp now owns 174,529 shares of the company's stock valued at $218,000 after purchasing an additional 40,500 shares during the last quarter. Opus Capital Group LLC increased its position in shares of SELLAS Life Sciences Group by 5.5% in the fourth quarter. Opus Capital Group LLC now owns 238,500 shares of the company's stock valued at $248,000 after buying an additional 12,400 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in SELLAS Life Sciences Group by 17.1% during the 3rd quarter. Geode Capital Management LLC now owns 605,191 shares of the company's stock valued at $757,000 after acquiring an additional 88,183 shares in the last quarter. Hedge funds and other institutional investors own 17.38% of the company's stock.

Remove Ads

SELLAS Life Sciences Group Trading Up 2.5 %

Shares of NASDAQ SLS traded up $0.03 during trading on Monday, reaching $1.23. The company had a trading volume of 1,239,251 shares, compared to its average volume of 1,407,753. The stock has a market capitalization of $86.57 million, a PE ratio of -1.78 and a beta of 2.43. SELLAS Life Sciences Group, Inc. has a twelve month low of $0.77 and a twelve month high of $1.84. The stock has a 50-day moving average price of $1.21 and a two-hundred day moving average price of $1.17.

SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.03. During the same period last year, the firm posted ($1.34) EPS. On average, sell-side analysts predict that SELLAS Life Sciences Group, Inc. will post -0.57 EPS for the current year.

SELLAS Life Sciences Group Profile

SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.